BioNTech guides for worse-than-expected 2025 revenue decline
German COVID-19 vaccine maker BioNTech on Monday said that its 2025 revenues would likely fall to between 1.7 billion euros ...
German court rules Pfizer, BioNTech violated Moderna's COVID-19 vaccine patent
A German court on Wednesday ruled that Pfizer and its partner BioNTech violated a COVID-19 vaccine patent held by Moderna. In ...
BioNTech initiated with a Buy at Citi
Citi analyst Geoff Meacham initiated coverage of BioNTech (BNTX) with a Buy rating and $145 price target Healthcare policy remains a key ...
Investopedia6d
BioNTech Stock Drops as Sales Outlook Disappoints
U.S.-listed shares of BioNTech fell Monday, as the COVID-19 vaccine maker’s soft sales outlook offset better-than-expected quarterly results. The German company said it expects 2025 total ...
BioNTech SE (BNTX) Gets a Buy from Deutsche Bank
Deutsche Bank analyst Emmanuel Papadakis maintained a Buy rating on BioNTech SE (BNTX – Research Report) today and set a price target of ...